Neogenomics Inc
NASDAQ:NEO
Net Margin
Neogenomics Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Neogenomics Inc
NASDAQ:NEO
|
807.4m USD |
-12%
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.1T USD |
10%
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
180.6B USD |
15%
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
147.1B USD |
14%
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
71.2T KRW |
26%
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
39.6B CHF |
10%
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
34.7B USD |
9%
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
34.1B USD |
18%
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
256.7B CNY |
27%
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26.3B USD |
22%
|
|
| IN |
|
Divi's Laboratories Ltd
NSE:DIVISLAB
|
1.8T INR |
24%
|
Neogenomics Inc
Glance View
NeoGenomics Inc. stands as a formidable player in the field of cancer diagnostics, carving out a niche where precision and innovation meet the urgent needs of patients and healthcare providers. Born out of the vision to advance cancer diagnostics through a blend of clinical testing and state-of-the-art technology, NeoGenomics offers oncologists and pathologists an extensive menu of tests that target genetic markers critical for cancer diagnosis and monitoring. The company operates through a network of high-complexity laboratories in the United States and a growing presence internationally, leveraging its vast technological capabilities to provide services like cytogenetics, molecular testing, and solid tumor testing. This breadth of service allows NeoGenomics to sit squarely at the intersection of patient care and the burgeoning field of personalized medicine. By anchoring its revenue streams primarily in laboratory services, NeoGenomics draws its financial strength from a diverse clientele of community-based healthcare providers, academic institutions, and pharmaceutical companies. The firm capitalizes on the demand for precision diagnostics, as more treatments necessitate an intimate understanding of the tumor’s genetic makeup. This careful calibration between cutting-edge science and clinical practice not only fuels its growth but also positions NeoGenomics as an indispensable partner in the continuum of cancer care. Additionally, its collaborations with pharmaceutical companies open doors to new revenue channels via companion diagnostic development and clinical trial support services, exemplifying an agile approach in the dynamic landscape of oncology.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Neogenomics Inc's most recent financial statements, the company has Net Margin of -11.5%.
You don't have any saved screeners yet